Ross M. Kedl

Dr. Kedl received his Ph.D. in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small-molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology.

​Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer. Dr. Kedl's extensive experience with vaccine development and industry operations will greatly help Nanoly in its goal to eliminate the need for refrigeration of vaccines and therapeutics.